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Long-term mortality and morbidity of 1,741 patients
with acute myocardial infarction, treated with intrave-
nous streptokinase (1.5 million IU/h) or placebo, was
assessedin a double-blind placebo-controlledtrial (ISAM).
At the 7 month follow-up, 94 (10.9%) of the 859 patients
in the streptokinase group and 98 (11.1%) of the 882
patients in the placebo group had died; at an average
follow-upof 21 months, 14.4% of the streptokinase group
and 16.1% of the placebo group had died. The differ-
ences were not statistically significant.
Long-term mortality was slightly higher in patients
with anterior myocardial infarction and streptokinase
treatment (20.1 versus 18.4%) and lower in patients with
In 1959, Fletcher et al. (I) were the first to use an intra-
venous streptokinase infusion in the treatment of acute myo-
cardial infarction. Between 1959 and 1974,1 15 prospective
randomized controlled trials (2) were carried out with a
prolonged intravenous streptokinase infusion over 12 to 24
hours. The majority of patients were entered into these trials
more than 6 hours after the onset of pain. Follow-up data
were available for some weeks only and, more important.
most of these earlier trials (3,4) remain equivocal because
Part ( of this Seminar appeared in the November 19H6 issue of the
Journal.
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inferior myocardial infarction (10.2 versus 14.2%). Pa-
tients with previous myocardial infarction had a higher
long-term mortality rate with streptokinase (34.9 versus
21.5% with placebo, p = 0.03). At 7 months, there were
significantly more cases of reinfarction in the strepto-
kinase group (7.2 versus 4.5%, p = 0.02).
It is concluded that despite a significant limitation of
infarct size by intravenous streptokinase, long-term
mortality is only slightly reduced and reinfarction is sig-
nificantly more frequent. Both findings suggest the need
for complementary therapy such as revascularization
procedures after thrombolysis.
(1 Am Coil Cardiol 1987;9:197-203)
of the study designed inappropriate according to today's
standards. Recently, data on in-hospital mortality and mor-
bidity in two randomized large scale multicenter trials of
high dose, brief duration intravenous administration of
streptokinase were published (5,6). Long-term results have
not been reported.
The ISAM study (6) was a prospective German-Swiss-
Canadian controlled double-blind multicenter trial, evalu-
ating the effect of 1.5 million IU of streptokinase or placebo
administered intravenously over 60 minutes within 6 hours
after the onset of symptoms of myocardial infarction.
Methods
Study patients. Between March 1982 and March 1985,
1,741 patients of either sex up to an age of 75 years were
included in the study from 38 hospitals: 1,573 from West
Germany and Switzerland and 168 from Canada. Of these
1,741 patients, 859 were randomly allocated to streptoki-
nase, 882 to placebo. Data analysis was based on "intention
0735-I097/X7/$350
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Figure 1. Cumulative 7 month mortality in patients allocated to
streptokinase or placebo treatment.
timated by meansof: I) serial serum enzyme activity curves,
b) serial 12 lead electrocardiograms and c) global and re-
gionalejection fraction fromcontrast ventricular angiograms
3 to 4 weeks after myocardial infarction; 4) patency of the
infarct-related coronary arteries by coronary angiography 3
to 4 weeks after myocardial infarction; 5) cardiac function
by means of a) measurement of right and left ventricular
hemodynamicsat rest and during exercise 3 to 4 weeks after
myocardial infarction; and b) exercise tolerance test after 7
months. B) To assess tolerability of the treatment regimen
with special emphasis on bleeding complications. Results
on 21 day mortality, morbidity and infarct size have been
published elsewhere (6).
Follow-up. Patients returned for follow-up examinations
at 4 and 7 months after randomization. At 7 months, routine
blood and biochemical tests were done, a chest X-ray film
was taken and an exercise tolerance test was performed. No
patient was lost to follow-up at 7 months. Data were re-
corded on standardized forms and were sent to the Data
Handling and Monitoring Center. Copies of the forms were
also sent directly from the clinical centers to the Coordi-
nating Center, enabling permanent cross-checking.
During the 7 months after entry into the study. all deaths,
nonfatal reinfarction and other nonfatal cardiac events were
reviewed by a Critical Event Committee. The members of
this committee were not otherwise involved in the trial and
did not have access to the treatment code. In case of dis-
agreement between the study physician and this committee,
the committee's classification was taken as final. Diagnosis
of reinfarction was based on the presence of at least two of
the following criteria: I) typical prolonged chest pain, 2)
development of new Q waves, and 3) a more than twofold
increase in serum cardiac enzymes.
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to treat" after original treatment allocation. The detailed
study design and list of participating centers, investigators
and committees have been published (6).
Objectives of the study. Primary end points. A) To
compare the effects of intravenous streptokinaseand placebo
administered within 6 hours after the onset of symptoms of
myocardial infarction on I) early (21 days) and 2) long-
term mortality. B) To compare the results in patients treated
within 3 hours and later than 3 hours after the onset of
symptoms.
Secondary end points: A) To compare the effects of
intravenous streptokinase and placebo on I) cardiac mor-
talityand the incidence of nonfatal cardiac events at 7 months;
2) the restoration of coronary blood flow estimated from
serial serum enzyme activity curves; 3) "infarct size," es-
Table 1. Cause-Specific 7 Month Mortality by Treatmenl Group
SK Placebo Relative Nominal
Group Group Risk p Value
Total deaths 94/859 98/882
Cardiac deaths 83 96 0.89 0.40
Sudden death 27 26
Ventricular fibrillation 4 6
AV block I I
Reinfarction 7 3 2.40 0.19
Cardiac failure 33 46 0.74 0.17
Cardiac rupture 10 13 0.79 0.57
Cardiac surgery I I
Noncardiac deaths II 2 2.55 0.01
Early bleeding 3 0
(treatment related)
Early embolism 2 0
Late bleeding 3 0
Late stroke 2 0
Other I 2
AV = atrioventricular; SK = streptokinase.
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Medication, particularly of beta-receptor blocking agents,
anticoagulants or acetylsalicylic acid, as reported in the 1,4
and 7 month visit form, was used to evaluate the balance
of treatment between the two groups and their potential
influence on survival.
Follow-up beyond 7 months concerned total mortality
only, evaluated by inquiries based on the government re-
gistry. For eight patients, four from each group, the vital
status could not be obtairted at the time of the final cutoff
date for the study. They were counted as being alive up to
the last date of ascertained information.
Results
Seven month mortality. During the 7 months after entry
into the study, there were 197 deaths, 94 (10.9%) in the
streptokinase group and 98 (II. 1%) in the placebo group.
The cumulative 7 month survival curve (Fig. I) shows that
the early trend toward a better survival in the streptokinase
group leveled off after 18 weeks. Between 22 days and 7
months, the mortality in patients with anterior myocardial
infarction was higher in the streptokinase group (22 (6.1 %)
of 359 patients, 19 cardiac deaths) than in the placebo group
(14 (3.6%) of 393 patients, 13 cardiac deaths).
Cause-specific 7 mo,nth mortality data are given in Table
I. There were 83 (9.7%) cardiac deaths in the streptokinase
group and 96 (10.9%) in the placebo group. The number
of sudden deaths, that is, persons with instantaneous wit-
nessed death or found dead, and deaths from ventricular
fibrillation were similar in both groups. Fatal reinfarctions
tended to be more common, and death from cardiac failure
less common in the streptokinase group.
Noncardiac deaths. There were II noncardiac deaths
in the streptokinase group compared with only 2 in the
placebo group (Table I). The two latter deaths were caused
by septicemia, one within and one later than 21 days. In
the streptokinase group, three deaths were related to bleed-
ing complications caused by the treatment regimen (6). Two
patients died of cerebral hemorrhage, the first symptoms
developing 5 and 12 hours, respectively, after initiation of
streptokinase infusion. One patient. who had severe gas-
trointestinal bleeding on the third day died after cerebral
symptoms developed (6). There were two deaths from em-
bolic events. One of these deaths might have been caused
by thrombolysis; the patient had atrial fibrillation for 10
years and abdominal symptoms developed I day after strep-
tokinasc infusion. Death occurred 2 days later and necropsy
showed bowel necrosis from mesenteric embolism. The other
embolic event leading to death was recurrent pulmonary
emboli after 10 days in a patient with insufficient anti-
thrombotic therapy.
Between 22 days and 7 months, there were six noncardiac
deaths in the streptokinase group, Two patients had a cere-
brovascular accident. One of them had a large intracerebral
hemorrhage I week after undergoing bypass surgery 4 weeks
after randomization. The other patient had a stroke 5 months
after streptokinase treatment; he had a 50% stenosis of the
internal carotid artery. Computed tomography could not
distinguish between hemorrhage and ischemia. There were
three fatal bleeding episodes; two of these, occurring 2 and
6 months, respectively, after randomization were strongly
related to an inappropriate dosage of anticoagulant agents.
There was no corresponding event in the placebo group.
Four weeks after randomization, gastrointestinal bleeding
was the terminal event in one more patient in the strepto-
kinase group, a patient with severe congestive heart failure.
Of interest is the history of the sixth patient. Four days after
streptokinase infusion, he developed signs of pulmonary
edema with normal pulmonary artery pressure; partial pres-
sure of oxygen (P02 ) was decreased to 36 mm Hg. He
recovered within 10 days, but was hospitalized 2 months
later because of severe dyspnea, hemoptysis and pulmonary
Table 2. Seven Month Incidence of Cardiac Events
SK
Reinfarction
Nonfatal
Fatal + nonfatal
Coronary bypass
surgery or PTCA
Angina pectoris
Congestive heart failure
Nonfatal
Fatal + nonfatal
Symptomatic
tachyarrhythmia after
21 (jays
No. of
Patients
54
61
107
123
25
58
16
6.3
7.2
12.5
14.3
2.9
6.6
19
Placebo
No. of
Patients 'k
37 4.2
40 4.5
84 9.5
110 12.5
34 3.9
80 9.1
12 14
Nominal
p Value
0.05
0.02
0.05
0.26
0.28
0.07
041
PTCA = percutaneous transluminal coronary angioplasty: SK = streptokinase.
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infi ltrations on X-ray fi lm. Hemoglobin was 7.0 g/dl, serum
creatinine 1.6 mg/dl and there was gross hematuria and
proteinuria. The patient died the same day. Goodpasture
syndrome was suggested; necropsy was not performed.
Seven month cardiac events (Table 2). In the placebo
group. more patients developed congestive heart failure. In
the streptokinase group. the rate of fatal or nonfatal rein-
Iarct ion was higher (7.2 versus 4.5 % in the placebo group.
p = 0.02) . During the first 12 weeks, the differences in the
reinfarction rates were continuously increasing (Fig. 2).
Reinfarction occurred in the same territory as the initial
infarct in 35 patients receiving placebo and in 53 receiving
streptokinase (Table 3). In patients with anterior wall in-
farction. the reinfarction rate was similar in both treatment
groups. However. in patients with an inferior wall infarc-
tion. the reinfarction rate in the same territory was signif-
icantly higher in the streptokinase group (29 patients versus
14 in the placebo group. p = 0.03).
Long-term mortality. With an average follow-up period
of 2 1 months. the percent of patients who died was 14.4%
in the streptokinase group ( 124 deaths) and 16.1% in the
placebo group ( 142 deaths). There was an apparent benefit
to the streptokinase group later than 18 months in the follow-
up period (Fig. 3). although the difference in cumulative
mortality rates was still far from being significant (log rank
test. p = 0.32) .
Table 4 shows long-term mortality results, analyzed by
selected baseline variables. A relative risk of less than I
indicates an observed lower mortality in the streptokinase
group. Most of the subgroups studied exhibited a trend that
is consistent with the overall trend of the study. Possible
exceptions with respect to in-hospital and long-term mor-
tality were the subgroups of patients with a history of pre-
vious myocardial infarction (p = 0.(3) or a history of hy-
pertension and women. In the latter. the mortality in the
Table 3. Site of Reinfarct ion (Numbe r orPatients )
Infarction at Randomization
Anterior Inferior
SK Placebo SK Placeho
Reinlarction Group Group Group Group
Anterior 24(3) 22(3) 3 2
Inferior 2 2 29(2) 14
Undefined 1(1 ) 2( I)
Anterior ~ anterior . anteroscptal and/or lateral wall infarction: Infe-
rior = inferior. interolateral and/or posterolateral wall infarction: SK =
streptokinase: Undefined = definite localization not possible. Numbers in
parentheses indicate fatal reintarctions.
streptokinase group tended to be higher regardless of age.
infarct localization. history of hypertension or previous
myocardial infarction. In the streptokinase group, the long-
term mortality of patients with anterior wall infarction was
slightly higher (20.1 versus 18.4%), and for patients with
inferior wall infarction it was lower ( 10.2 versus 14.2lJk,)
than in the placebo group.
Mortality after the 4 month visit was compared for users
and nonusers of beta-receptor blocking agents. anticoagulant
agents or acetylsalicylic acid. There was some trend toward
increased survival in patients in the placebo group who used
these drugs individually or in combination. In the strepto-
kinase group. such a trend was only apparent in patients
treated with anticoagulant agents. The medication used was
similar in the two treatment groups. About 40% received
beta-blockers. 30% anticoagulants and 20% acetylsalicylic
acid. These data were considered useful to estimate whether
long-term mortality of the study groups was seriously af-
fected by the medical treatment practiced. There was no
significant difference for any subgroup tested.
Figure 2. Seven month probability of reinfarc tion in patients a~­
located to streptokinase or placebo treatm ent . Log-rank test: chi-
square = 4 .52, P = 0 .02.
Figure 3. Cumulative long-term mortality in patients alloca ted to
streptoki nase (STK) or place bo (PLA) treatment (log-rank test.
p = 0 .32). Patients at risk at various follow-up intervals are given
above the x axis .
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Table 4. Long-term Mortality by Baseline Variables in Both Treatment Groups
SK Group Placebo Group
No. of No. of Relative Nominal
Patients (I< Patients o/r Risk p Value
Treatment
< 3 Hours 62/477 12.9 70/463 15.1 0.86 (US
> 3 Hours 57/365 15.6 68/405 16.8 0.93 0.66
Male 89/694 13.0 115/727 15.8 0.81 0.1\
Female 35/165 21.2 271155 17.4 1.21 0.39
Age (yr)
< 50 5/170 2.9 IIIIXO 6.1 0.48 0.16
50 to <65 50/426 11.7 55/430 12.8 0.91 0.64
65 to <70 321\32 24.2 30/1 16 25.9 0.93 0.77
:0- 70 371\31 28.2 46/156 29.5 0.96 0.82
Site of infarction
Anterior 74/368 20.1 76/413 18.4 1.09 0.55
Lateral \I 26 3.8 \I 21 4.7
Inferior 46/448 10.2 61/429 14.2 o.n 0.07
Undefined 3/ 16 21.4 4/ 19 21.0
Medical history
Hypertension 36/202 17.8 29/204 14.2 1.25 0.32
Previous MI 37/106 34.9 22/102 21.5 1.62 0.03
Angina pectoris> 4 weeks 57/299 19.0 62/280 22.1 0.86 0.36
Cardiac failure 18/ 93 19.3 24/ 89 26.9 o.n 0.22
Diabetes mellitus 25/1 II 22.5 32/ 96 33.3 0.67 0.08
Conditions at randomization
Heart failure 4811X3 26.2 621190 32.6 0.80 0.17
Tachycardia> 100/min 30/ 95 31.5 31/ 91 34.0 0.92 o.n
Bradycardia < 60/min 13/141 9.2 22/145 15.2 0.61 0.13
AV block, 2° or 3° 3/ 28 10.7 8/ 31 25.8 0.43 0.14
QRS :0- 0.12 second 19/ 47 40.4 22/ 55 40.0 1.01 0.96
VES:o- 10/min 33/165 20.0 40/168 23.8 0.87 0.40
MI = myocardial infarction; YES = ventricular extra systoles; other abbreviations as in Table I.
Discussion
In the Intravenous Streptokinase in Acute Myocardial
Infarction (ISAM) trial, the in-hospital mortality rate in
patients treated with streptokinase was 15% lower than in
the placebo-treated patients (6). Treatment was initiated within
6 hours after the onset of myocardial infarction. but only
rarely (2,6% of cases) within the first hour. In an unusually
large. controlled but open Italian Trial (GISSI) (5). the in-
hospital mortality rate in patients treated between I and 6
hours from symptom onset was also 15% lower in the strep-
tokinase group than in patients receiving conventional treat-
ment. However. in GISSI. a difference of 47% in favor of
streptokinase was observed in the 1.277 patients (10,8%)
treated within I hour from symptom onset. suggesting a
striking benefit only with very early intravenous streptoki-
nase therapy (5),
Long-term mortality. The ISAM trial (6) demonstrated
a significant limitation of creatine kinase. MB fraction (CK-
MB) measured infarct size and a preservation of left ven-
tricular function in the streptokinase group, Because it has
been apparent from postinfarction studies (7-9) that the
degree of left ventricular dysfunction has a considerable
influence on mortality. an increasingly favorable long-term
outcome for streptokinase-treated patients was anticipated.
However. during the first 7 months after entry into the study.
the initial trend toward a lower mortality with streptokinase
treatment leveled off (Fig. I). Most likely by chance. there
were more late deaths from noncardiac causes in the strep-
tokinase-treated patients. However. after hospital discharge
at 7 months. there was also a higher cardiac mortality in
those streptokinase-treated patients with an anterior wall
infarction. In general. only after more than 18 months was
there again an apparent benefit for the streptokinase group
(Fig. 3). This finding suggests that. although there is a
favorable long-term outcome for many patients. others have
an increased risk of dying. Such a temporarily increased
risk for certain streptokinase-treated patients cannot yet be
readily explained by our data.
At 7 months. the proportion of deaths due to pump failure
was lower in the streptokinase group (Table I). a finding
logically explained by a less compromised left ventricular
function. However. in the streptokinase group the reinfarc-
tion rate was significantly higher (Fig. 2). The rate of sudden
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death was similar in both groups despite a less compromised
left ventricular function in the streptokinase group. Because
the severity of left ventricular dysfunction is a major de-
terminant of mortality in general, as well as of sudden death
in survivors of myocardial infarction (7-9), streptokinase-
treated patients apparently are in an unstable situation with
greater vulnerability to recurrent myocardial infarction and
sudden death. At particular risk are patients with a history
of previous myocardial infarction. In this subgroup with
probably more severe left ventricular dysfunction, the long-
term mortality rate was 34.9% in the streptokinase group
and 21.5% in the placebo group (Table 4). Currently further
subgroup analyses are being undertaken, attempting a more
specific identification of patients at risk. Apparently, an
increased risk of dying cumulates in patients with large
anterior wall infarction, and particularly in those who had
a rapid restoration of coronary blood flow, as manifested,
by peaking of serum CK-MB within 9 hours after the start
of treatment.
Potential clinical instability in streptokinase-treated
patients. Successful intravenous thrombolysis can at best
reestablish the coronary anatomy to its condition before the
acute thrombotic occlusion. In many patients a serve resid-
ual stenosis continues to pose the same hazard as before
(10). The potentially unstable situation in streptokinase-
treated survivors of acute myocardial infarction, first dem-
onstrated here in a double-blind placebo-controlled trial,
raises the question of the need for additional mechanical or
surgical intervention. Immediate (11- 13) or early elective
(10,13) percutaneous coronary angioplasty in suitable pa-
tients with proximal obstruction involving one or two ar-
teries has been advocated and seems logical and appealing.
The safety and feasibility of coronary bypass grafting several
days after intracoronary streptokinase therapy in those pa-
tients with more extensive or distal disease have also been
demonstrated (14,15) . However, randomized trials of suf-
ficient statistical power are required to ascertain the true
impact of such "definitive treatment" (16).
An improved I year survival rate with intracoronary
administration preceded by intravenous administration of
streptokinase as compared with conventional treatment was
reported from a trial of 533 patients conducted in The Neth-
erlands (13). Coronary angioplasty immediately or later on
and aortocoronary bypass grafting were performed in 39%
of the streptokinase group and 15% of control patients.
These figures are considerably higher than in our trial, in
which angioplasty or surgery was performed in only 12.5%
of the streptokinase-treated and 9.5% of the placebo-treated
patients (Table 2).
Role of site of coronary thrombosis and myocardial
infarction. In patients with initial anterior wall infarction,
the 7 month reinfarction rate in the same territory was sim-
ilarly high in both study groups, whereas mortality after
discharge from the hospital was higher in the streptokinase
group. Among patients with inferior wall myocardial in-
farction, the reinfarction rate in the streptokinase group was
as high as that in patients with anterior wall infarction. In
the placebo group, however, the reinfarction rate was sig-
nifi cantly lower (Table 3). These unexpected findings need
further consideration.
In a subgroup of 734 patients with serial CK-MB activity
curves and angiography aft er 4 weeks. we compared early
reperfusion according to peak CK-MB 13 hours or less after
the start of treatment and vessel patency at 4 weeks (17).
The right coronary artery was reoccluded in 20% of the
streptokinase and in 5% of the placebo group. This is con-
sistent with the higher reinfarction rate in streptokinase-
treated patients with initial inferior wall infarction as com-
pared with placebo-treated patients. In 16 of 29 streptoki-
nase-treated patients with inferior wall infarction (Table 3),
reinfarction occurred within the first 21days, that is, during
the hospital stay. Under these conditions death often can be
prevented.
Reperfusion rates of the le./i anterior descending coro-
nary artery were higher than those of the right coronary
artery; reocclusion at 3 to 4 weeks was seen in only 9% of
the streptokinase and in 6% of the placebo group (17). In
keeping with this, there were fewer anterior wall reinfarc-
tions within 21 days, 7 in the streptokinase and 6 in the
placebo group. Between 22 days and 7 months, however,
17 patients in the streptokinase group and 16 in the placebo
group with initial anterior wall infarction had a reinfarction
in the same territory. Thus, proved reinfarction and, prob-
ably more often, reocclusion in patients with anterior wall
infarction usually occurred after discharge from hospital.
Fatal established reinfarctions in the same territory in
patients with anterior wall infarction were seen in only three
streptokinase- and three placebo-treated patients (Table 3).
Lethal recurrent ischemic events were mainly sudden deaths
(Table 2), which explains the higher cardiac mortality after
hospital discharge in streptokinase-treated patients with an-
terior myocardial infarction. However, it is not clear why
the reinfarction rate in patients with anterior wall infarction
is similarly high in both treatment groups. In patients with-
out thrombolysis, early peaking in the serum CK-MB ac-
tivity curve evidences spontaneous reperfusion (18). These
patients develop a smaller infarct; however, they have a
significantly increased rate of reinfarction (19). Among pa-
tients in the placebo group whose left anterior descending
artery was indentified as the infarct-related coronary artery,
about one-third had an early CK-MB peak (17). This may,
at least in part, explain the relatively high reinfarction rate
in placebo-treated patients.
Conclusions. Although a significant limitation of infarct
size has been proved in patients with high dose, brief du-
ration intravenous infusion of streptokinase within the first
6 hours from onset of myocardial infarction symptoms (6),
the long-term course after hospital discharge was unsatis-
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factory. The reinfarction rate was higher than in placebo-
treated patients and the long-term mortality not signifi cantly
different in the two treatment groups. After successful
thrombolysis there is the risk of rethrombosis and further
myocardial necrosis, by which the temporary benefits of
thrombolytic therapy are lost. Further studies are needed to
determine whether long-term antithrombotic therapy, early
percutaneous coronary angioplasty. bypass surgery or a
combination of these can improve the long-term outcome
in patients with acute myocardial infarction and successful
intravenous thrombolytic therapy.
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